Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Thymosin-alpha-1

Thymalfasin, Zadaxin, Thymosin α1

Quick Stats
Studies 759
Trials 63
Score 2
2019 pubmed

Chronic active EBV infection associated with NK cell lymphoma and hemophagocytic lymphohistiocytosis in a 27-year-old woman: A case report.

Wang. Ya-Dong YD; Wu. Ling-Ling LL; Ma. Lu-Yuan LY; Shang. Xiao-Bo XB; Li. Zi-Yue ZY; Wang. Wei W; Shen. Chuan C; Yang. Jing-Jing JJ; Sun. Li-Xia LX; Zhao. Cai-Yan CY

Key Findings

  • Chronic active EBV can progress to NK‑cell lymphoma and HLH, especially with liver involvement.
  • Thymosin‑alpha‑1 was used as an adjuvant therapy but did not prevent disease progression in this case.
  • Diagnosis relied on EBV‑encoded RNA in‑situ hybridization and bone‑marrow flow cytometry, and treatment required aggressive antivirals, steroids, etoposide, and chemotherapy.

Practical Outcomes

  • For self‑directed health optimizers, thymosin‑alpha‑1 should be viewed as a supportive add‑on, not a cure, for severe EBV‑related conditions. Early detection of CAEBV and prompt, aggressive treatment are crucial, and relying on thymosin‑alpha‑1 alone is unlikely to prevent fatal outcomes.

Summary

A 27‑year‑old woman with chronic active Epstein‑Barr virus infection developed a deadly combo of NK‑cell lymphoma and a severe immune reaction called HLH. Doctors tried antivirals, steroids, and thymosin‑alpha‑1, but the disease kept getting worse and she eventually died. The case shows that thymosin‑alpha‑1 alone isn’t enough to stop serious EBV‑related complications.

Abstract

Chronic active Epstein-Barr virus infection (CAEBV) is a common infectious disease that often affects multiple organs or systems. However, it is liable to be neglected and misdiagnosed owing to its insidious onset, lack of specific findings in the early phase, and a general lack of awareness among clinicians. PATIENT CONCERNS:: a 27-year-old woman case has been described who was initially misdiagnosed as drug-induced liver injury due to onset presentation of mild splenomegaly, recurrent liver dysfunction, and disputable pathological evidence of liver biopsy. CAEBV complicated with natural killer (NK) cell lymphoma and hemophagocytic lymphohistiocytosis (HLH) was diagnosed by in situ hybridization of liver tissue section with EBV-encoded RNA -1 probe and flow cytometry of bone marrow. After admission, the patient received symptomatic treatment and antiviral therapy (combination of acyclovir and foscarnet sodium) as well as adjuvant treatment (thymosin alpha 1 and methylprednisolone); later, the patient received etoposide and dexamethasone for diagnosis of EBV associated HLH. Subsequently, the disease progressed to NK cell lymphoma and the patient received the revised EPOCH chemotherapy regimen [etoposide (100 mg/d, d1-5), dexamethasone (7.5 mg/d, d1-5; 5 mg/d, d6-14), cyclophosphamide (0.8 g/d, d1-2), and pegaspargase (3750 u/d, tid, d1-2)]. Although the patient received a series of therapies and other comprehensive measures, finally she died of gastrointestinal hemorrhage and multiple organ failure. Liver is one of the main target organs of EBV infection. In the clinical setting of unexplained fever and liver injury, it is necessary to be aware of CAEBV, as well as its fatal complication such as EBV associated NK cell lymphoma and HLH.

Study Information

Provider

pubmed

Year

2019

DOI

10.1097/md.0000000000014032